Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON (Degarelix) or a GnRH Agonist

NCT01234350 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT01234350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01234350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON (Degarelix) or a GnRH Agonist
Lead sponsor
Ferring Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
January 31, 2011
Completion date
March 27, 2018
Enrollment
1,493 (actual)
Sites
160

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer